Mindel A
Academic Department of Genito Urinary Medicine, University College & Middlesex School of Medicine, London, U.K.
Scand J Infect Dis Suppl. 1991;80:27-32.
The introduction of acyclovir a safe and efficacious antiviral agent has revolutionised the treatment of recurrent orolabial and genital herpes. The treatment of each recurrence with topical or oral acyclovir is of limited benefit. However, long term suppression with oral acyclovir is highly effective. Patients should be considered for therapy on the basis of the frequency and severity of recurrence, and any associated psychosexual morbidity. Treatment should be commenced at a dose of 200 mg qds. Subsequent reduction in dose may be possible. Treatment should continue for 1 year then be stopped in order to ascertain if the frequency of recurrence still warrants suppression. The reasons for failure to respond to long term suppression or relapse include malabsorption and the emergence of drug resistant strains.
阿昔洛韦（一种安全有效的抗病毒药物）的引入彻底改变了复发性唇疱疹和生殖器疱疹的治疗方法。每次复发使用局部或口服阿昔洛韦治疗的益处有限。然而，口服阿昔洛韦进行长期抑制治疗非常有效。应根据复发的频率和严重程度以及任何相关的性心理疾病来考虑对患者进行治疗。治疗应开始于200毫克每日四次的剂量。随后可能可以减少剂量。治疗应持续1年，然后停药以确定复发频率是否仍需要抑制治疗。对长期抑制治疗无反应或复发的原因包括吸收不良和耐药菌株的出现。
